CRYO: AI 评分 46/100 — AI 分析 (4月 2026)

American CryoStem Corporation focuses on developing and marketing adipose tissue-derived technologies for regenerative and personalized medicine. Their offerings include tissue collection systems, storage services, and cell culture media, targeting the anti-aging and regenerative medicine markets.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

American CryoStem Corporation develops and licenses adipose tissue-derived technologies for regenerative medicine, offering products like CELLECT and ATGRAFT. Operating within the biotechnology sector, the company provides solutions for tissue collection, storage, and cell culture, targeting personalized medicine applications, while facing competition in a dynamic market.

CRYO是做什么的？

American CryoStem Corporation, founded in 1987 and based in Eatontown, New Jersey, is a biotechnology company focused on regenerative and personalized medicine. The company develops, markets, and licenses technologies derived from adipose tissue. Its core offerings include the CELLECT collection, transportation, and storage system, designed to facilitate the collection and delivery of tissue samples by physicians. ATGRAFT adipose tissue storage service provides a comprehensive solution for fat collection, processing, and storage, enabling physicians to offer tissue products and cell storage options to their patients. ATCELL adipose-derived stem cells are also part of their product line. Additionally, American CryoStem offers ACSelerat cell culture media products, specifically formulated for growing human stromal cells. Beyond its core product lines, the company provides contract manufacturing services for Autokine-CM, an anti-aging topical formulation, and an autologous skin care product line. American CryoStem aims to be a key player in the regenerative medicine field by providing comprehensive solutions for tissue and cell-based therapies.

CRYO的投资论点是什么？

American CryoStem Corporation operates in the burgeoning regenerative medicine sector, offering potential for growth as personalized medicine gains traction. However, the company's negative P/E ratio of -0.00 and a significantly negative profit margin of -13985.4% raise concerns about its financial sustainability. A high beta of 11.42 indicates extreme volatility, making it a high-risk investment. Key value drivers include the expansion of its product line and strategic partnerships within the regenerative medicine space. Upcoming catalysts involve the potential FDA approvals for adipose tissue-derived therapies. However, the company's small size, with only 4 employees, and its listing on the OTC market present significant risks.

CRYO在哪个行业运营？

American CryoStem Corporation operates within the regenerative medicine and biotechnology industry, a sector characterized by rapid innovation and increasing demand for personalized therapies. The market is driven by advancements in stem cell research and a growing aging population seeking anti-aging solutions. The competitive landscape includes companies focused on cell therapies, tissue engineering, and regenerative medicine products. American CryoStem's focus on adipose tissue-derived technologies positions it within a niche segment of this broader market, requiring it to compete with both specialized firms and larger players in the biotechnology space.

Biotechnology

Healthcare

CRYO有哪些增长机遇？

Expansion of CELLECT System Adoption: The CELLECT collection, transportation, and storage system offers a growth opportunity by targeting physicians seeking efficient tissue sample handling solutions. The market for such systems is growing as regenerative medicine practices expand. Increased adoption could be driven through targeted marketing and partnerships with medical clinics, potentially capturing a larger share of the tissue collection market within the next 2-3 years.
Increased ATGRAFT Service Utilization: The ATGRAFT adipose tissue storage service can drive growth by catering to patients seeking long-term storage of their tissue for future regenerative therapies. As awareness of regenerative medicine benefits increases, demand for tissue storage services will likely grow. By offering competitive pricing and secure storage solutions, American CryoStem can attract more customers and expand its storage service revenue within the next 5 years.
Development of Novel ACSelerat Media Formulations: The ACSelerat cell culture media products present a growth opportunity by catering to researchers and institutions involved in cell-based therapies. The market for cell culture media is expanding with advancements in cell biology and regenerative medicine. Developing specialized media formulations for different cell types can differentiate American CryoStem and capture a larger share of the cell culture media market within the next 3-4 years.
Strategic Partnerships for Autokine-CM Manufacturing: The contract manufacturing services for Autokine-CM, an anti-aging topical formulation, offer a growth opportunity by leveraging existing manufacturing capabilities. Partnering with dermatology clinics and skincare companies can expand the reach of Autokine-CM and increase manufacturing revenue. Establishing long-term manufacturing agreements can provide a stable revenue stream within the next 2 years.
Licensing of Adipose Tissue-Derived Technologies: Licensing its adipose tissue-derived technologies to other companies in the regenerative medicine space can generate revenue and expand market reach. The demand for innovative regenerative medicine technologies is high. By actively seeking licensing agreements, American CryoStem can monetize its intellectual property and establish a presence in new markets within the next 3-5 years.

Market Cap of $0.00B indicates the company is a microcap stock with limited liquidity.
P/E Ratio of -0.00 reflects the company's lack of profitability.
Profit Margin of -13985.4% highlights significant financial challenges.
Gross Margin of 34.1% suggests some efficiency in core operations despite overall losses.
Beta of 11.42 indicates extreme volatility compared to the market.

CRYO提供哪些产品和服务？

Develop adipose tissue-derived technologies.
Market regenerative and personalized medicine solutions.
Offer CELLECT collection, transportation, and storage systems for tissue samples.
Provide ATGRAFT adipose tissue storage services.
Offer ATCELL adipose-derived stem cells.
Supply ACSelerat cell culture media products.
Provide contract manufacturing services for Autokine-CM.
Offer an autologous skin care product line.

CRYO如何赚钱？

Selling CELLECT collection, transportation, and storage systems to physicians.
Providing ATGRAFT adipose tissue storage services to patients.
Selling ACSelerat cell culture media products to researchers and institutions.
Generating revenue through contract manufacturing services for Autokine-CM.
Licensing adipose tissue-derived technologies to other companies.

Physicians seeking tissue collection and storage solutions.
Patients interested in regenerative medicine and tissue storage.
Researchers and institutions involved in cell-based therapies.
Dermatology clinics and skincare companies utilizing Autokine-CM.
Other companies in the regenerative medicine space licensing technologies.

Proprietary adipose tissue-derived technologies.
Established presence in the regenerative medicine market since 1987.
Comprehensive product line including collection systems, storage services, and cell culture media.
Contract manufacturing capabilities for specialized formulations like Autokine-CM.

什么因素可能推动CRYO股价上涨？

Upcoming: Potential FDA approvals for adipose tissue-derived therapies.
Ongoing: Expansion of strategic partnerships within the regenerative medicine space.
Ongoing: Increasing adoption of CELLECT collection system by physicians.
Ongoing: Growing demand for ATGRAFT adipose tissue storage services.
Ongoing: Development of new ACSelerat cell culture media formulations.

CRYO的主要风险是什么？

Potential: Intense competition in the regenerative medicine market.
Potential: Regulatory hurdles and approval delays.
Potential: Technological advancements rendering current technologies obsolete.
Ongoing: Negative profitability and high operating losses.
Ongoing: Limited financial disclosure due to OTC Other status.

CRYO的核心优势是什么？

Proprietary adipose tissue-derived technologies.
Comprehensive product line covering collection, storage, and cell culture.
Contract manufacturing capabilities for specialized formulations.
Established presence in the regenerative medicine market.

CRYO的劣势是什么？

Negative profitability and high operating losses.
Small size and limited resources.
High beta indicating extreme volatility.
Dependence on a niche market segment.

CRYO有哪些机遇？

Expansion of CELLECT system adoption.
Increased ATGRAFT service utilization.
Development of novel ACSelerat media formulations.
Strategic partnerships for Autokine-CM manufacturing.

CRYO面临哪些威胁？

Intense competition in the regenerative medicine market.
Regulatory hurdles and approval processes.
Technological advancements rendering current technologies obsolete.
Economic downturn impacting demand for regenerative medicine services.

CRYO的竞争对手是谁？

American Bio Medica Corporation — Focuses on developing and marketing rapid, point-of-care diagnostic tests. — (ABMC)
Andretti Acquisition Corp. — A special purpose acquisition company (SPAC). — (ACCA)
Allied Healthcare Products, Inc. — Manufactures and supplies respiratory therapy equipment. — (AHPIQ)
CRISPR Medicine Innovation Co., Ltd. — Focuses on CRISPR-based gene editing technologies. — (CRXM)
DMC Global Inc. — Provides technical products and services to the energy, industrial, and infrastructure markets. — (DMTKQ)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: John S. Arnone
Headquarters: Eatontown, US
Employees: 4
Founded: 2010

AI Insight

AI analysis pending for CRYO

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does American CryoStem Corporation do?

American CryoStem Corporation develops, markets, and licenses adipose tissue-derived technologies for regenerative and personalized medicine. Their core products include the CELLECT system for tissue collection, ATGRAFT for adipose tissue storage, and ATCELL adipose-derived stem cells. They also offer ACSelerat cell culture media and contract manufacturing services for anti-aging formulations, targeting physicians, researchers, and patients in the regenerative medicine market.

What are the main revenue streams for American CryoStem Corporation?

American CryoStem Corporation generates revenue through several streams, including the sale of CELLECT collection systems to physicians, fees for ATGRAFT adipose tissue storage services, sales of ACSelerat cell culture media to researchers, and contract manufacturing services for products like Autokine-CM. Licensing of their adipose tissue-derived technologies to other companies also contributes to their revenue.

What are the main risks for CRYO?

The main risks for American CryoStem Corporation include intense competition in the regenerative medicine market, regulatory hurdles for adipose tissue-derived therapies, and the potential for technological advancements to render their current technologies obsolete. Additionally, the company's negative profitability, high operating losses, and limited financial disclosure due to its OTC Other status pose significant financial risks.